Cargando…

CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient

Detalles Bibliográficos
Autores principales:	Kogel, Ann-Kathrin, Gold, Ralf, Schneider, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505348/ https://www.ncbi.nlm.nih.gov/pubmed/34175973 http://dx.doi.org/10.1007/s00415-021-10661-z

Ejemplares similares

Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate
por: Bollo, Luca, et al.
Publicado: (2022)

COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020)

COVID-19 in multiple sclerosis patients treated with dimethyl fumarate
por: Capone, Fioravante, et al.
Publicado: (2021)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
por: Sangurdekar, Dipen, et al.
Publicado: (2019)

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
por: Longbrake, Erin E, et al.
Publicado: (2015)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
por: Hammer, Anna, et al.
Publicado: (2018)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
por: Blumenfeld Kan, S, et al.
Publicado: (2019)

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015)

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
por: Kappos, L, et al.
Publicado: (2015)

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Severe pneumonia with formation of a pulmonary cavity associated with long-term rituximab therapy in multiple sclerosis
por: Schwake, Carolin, et al.
Publicado: (2020)

Dimethyl fumarate transfer into human milk
por: Ciplea, Andrea I., et al.
Publicado: (2020)

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions
por: Zinger, Nicole, et al.
Publicado: (2022)

No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
por: Piervincenzi, Claudia, et al.
Publicado: (2022)

Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis
por: Guerriero, Claudia, et al.
Publicado: (2022)

Dimethyl fumarate prevents ferroptosis to attenuate acute kidney injury by acting on NRF2
por: Yang, Yunwen, et al.
Publicado: (2021)

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
por: Viglietta, Vissia, et al.
Publicado: (2015)

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate
por: Nicholas, Jacqueline Ann, et al.
Publicado: (2014)

Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method
por: Gold, Ralf, et al.
Publicado: (2023)

Bacterial meningitis in a patient with multiple sclerosis receiving Tysabri
por: Moghadasi, Abdorreza Naser, et al.
Publicado: (2016)

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
por: Briner, Myriam, et al.
Publicado: (2019)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a3ajvsiaddogh85ieub95tjvq0